两株鼠抗人GL50单克隆抗体的制备及其生物学特性的初步研究

目的　研制鼠抗人GL5 0分子单克隆抗体并对其生物学特性进行初步研究。方法　以天然高表达人GL5 0分子的Daudi细胞为免疫原 ,人GL5 0 L92 9转基因细胞为目的单克隆抗体(McAb)的筛选细胞 ,采用B淋巴细胞杂交瘤技术 ,获得分泌特异性鼠抗人GL5 0分子McAb的杂交瘤细胞株 ;免疫荧光标记和流式细胞术分析McAb识别GL5 0的表达 ;Westernblot检测抗体对特异性细胞膜蛋白的识别 ;台盼蓝 (Trypanblue)染色细胞计数法和MTT法检测McAb对Daudi细胞体外生长的抑制作用 ;3 H TdR法检测抗体对GL5 0 L转基因细胞介导的活化T细胞体外增殖的效应。结果　成功制备 2株分泌特异性抗人GL5 0抗体的杂交瘤细胞株 12B11和 11C4 ;两者皆为IgG2a亚型 ;腹水效价皆在 1∶10 0 0以上 ;12B11、11C4特异性地识别GL5 0分子。 11C4McAb可以明显抑制Daudi细胞在体外的生长 ,并可抑制GL5 0 L转基因细胞介导的活化T淋巴细胞的体外增殖效应。结论　成功获得了 2株特异性鼠抗人GL5 0抗体 ,其中 11C4McAb具有诱导表达GL5 0分子的B淋巴瘤细胞Daudi的体外生长抑制作用 ;在T淋巴细胞体外增殖反应中发挥了重要的调节作用。     

大鼠肝抑素纯化及其生物活性的检测

用ＳｅｐｈａｄｅｃＧ－５凝胶过滤层析法，进一步纯化具肝抑素生物活性的大鼠肝蛋白质粗提品，以分离的大鼠再生肝的肝细胞为靶细胞，体外检测各洗脱峰浓缩物对肝细胞增殖的制率结果证明，Ｅ峰浓缩物的抑制作用最强，其活性比为粗提品的２０倍，ＳＤＳ聚丙烯酰胺电泳图及蛋白质迁移率测定表明，该浓缩物的主要成分为分子量１３．５ｋＤ的多肽。本研究对大鼠肝抑素做了初步纯化，验证了该物质在肝再生中起重要调控作用的生物效应。     

Familial amyloidotic polyneuropathy (ATTR Ser50Ile): the first autopsy case report

We report an autopsy case of a pedigree of familial amyloidotic polyneuropathy (FAP) with a mutation of isoleucine-50 transthyretin (ATTR Ser50Ile). A 47-year-old man started developing severe diarrhea and weight loss at age 41 years, followed by urinary incontinence, autonomic-nervous-system abnormalities and serious heart failure; the diagnosis of FAP (ATTR Ser50Ile) was made on the basis of genetic, histochemical and immunohistochemical analysis. Six years after the initial symptoms, he died of septic shock. Autopsy revealed suppurative peritonitis, perforation of the sigmoid colon and marked systemic amyloid deposition. The total amount of amyloid deposited in the heart was greatly increased and was much lower in the thyroid gland and kidneys compared with amyloid deposits in ordinary FAP (ATTR Val30Met). Amyloid deposition in peripheral vessel walls was prominent, particularly in lymphatics and veins. His elder sister, 54 years old, started to develop orthostatic hypotension at age 49 years, followed by dysesthesia, diarrhea and severe congestive heart failure. Endomyocardial biopsy revealed severe TTR–amyloid deposition; ultrastructural examination demonstrated that amyloid fibrils were deposited disproportionately and extended radially around microvessels. These characteristic patterns of systemic amyloid deposition and distinct clinical manifestations, especially in the cardiovascular system, are considered to be a characteristic feature of ATTR Ser50Ile amyloidosis. Received: 31 August 1999 / Accepted: 19 October 1999     

Expression of intercellular adhesion molecule-3 (ICAM-3/CD50) in malignant lymphoproliferative disorders and solid tumors

ICAM-3/CD50 is a recently described LFA-1 counter receptor that seems to play an important role in the initiation of immune responses. In this study we have examined the expression of ICAM-3/CD50 in a large series of human neoplasms including 101 Non-Hodgkin's lymphomas (NHL), 26 Hodgkin's disease, and 38 solid tumors to define the distribution patterns of this molecule in malignant neoplasms and their possible correlation with clinical and pathological characteristics of the patients. In NHL, ICAM-3/CD50 was expressed in almost all the tumors with a tendency to be lost in high grade lymphomas. Reed-Sternberg cells and their variants in Hodgkin's disease were always negative independently of the histological subtype of the disease. No expression was observed in tumor epithelial cells of the 38 solid tumors examined. Strong endothelial cell staining was observed in 31% of the NHL and 31% of Hodgkin's disease. ICAM-3 expression in these cases was restricted to small tumor vessels. ICAM-3 expression in endothelial cells of NHL was significantly more frequent in high grade (40%) than in low grade lymphomas (14%) (p=0.012). In addition, tumor vessels were also positive in 29% of solid rumors independently of the histological type. No correlation was observed between ICAM-3 expression in tumor or endothelial cells and other clinical and pathological characteristics of the patients. These findings indicate that ICAM-3 expression in human tumors is restricted to hematological neoplasms with a tendency to be lost in high grade lymphomas and Hodgkin's disease. ICAM-3 is also expressed by endothelial cells from tumor-associated neovascularization in both lymphoid and solid tumors.     

GPR34-mediated sensing of lysophosphatidylserine released by apoptotic neutrophils activates type 3 innate lymphoid cells to mediate tissue repair

1. Download : Download high-res image (200KB)
2. Download : Download full-size image

     

Reactivity of a monoclonal antibody produced to the histidine-rich protein of Plasmodium lophurae with Plasmodium falciparum

Monoclonal antibodies were produced against the histidine-rich protein of Plasmodium lophurae and tested for reactivity with Plasmodium falciparum antigens. One anti-histidine-rich protein monoclonal antibody showed immunological cross-reactivity with polypeptides of P. falciparum synthesized in vivo and in vitro.     

中国东北汉族一个先天性白内障家系致病基因的鉴定

目的鉴定一个先天性白内障家系的致病基因。方法根据已知与先天性白内障有关的12个致病基因的染色体上的定位,分别选取3～4个的微卫星标记位点,对该家系进行连锁分析。通过测序鉴定致病基因。结果在1q21.1GJA8位点显示最大Lod值2.44。致病基因定位于1q21.1区的GJA8基因,构成缝隙连接的缝隙连接蛋白Connexin50。DNA序列分析鉴定显示其第2外显子的第191个碱基杂合突变T>G导致其蛋白产物第64位缬氨酸转变为甘氨酸。结论Connexin50的V64G新生突变是导致该家系的致病原因。     

Sephadex—G50微柱凝胶血型试剂的研制和应用

目的 研制卡式微柱凝胶血型试剂并应用于血型血清学试验。方法 以Sephadex-G50超细凝胶为分子筛载体，制备成中性微柱凝胶试剂卡、特异性凝胶试剂卡及coomb’s凝胶试剂卡并用于血型鉴定、配血试验、抗体筛选和鉴定，对1000名献血者ABO及Rh（D）血型进行鉴定，其中A型272例、B型279例、B3亚型1例、0型437例、AB型11例；Rh（D）阴性2例，Rh（D）阳性998例；对100例输血前检查标本进行配血试验；以Coomb＇s凝胶试剂卡对抗-D、-C、-c、-E、-e、-Jk^a、-Jk^b、-Fy^a、-Di^a等9个抗体分别与谱红细胞反应做特异性抗体鉴定试验：同时以瑞士进口的DiaMed同类产品及常规的血型血清学试管法同步比较。结果 研制的卡式微柱凝胶血型试剂与瑞士进口的DiaMed同类产品比较，检验结果、敏感性、特异性无明显差别。结论 研制的卡式微柱凝胶试剂适用于血型鉴定、配血试验、抗体筛选和鉴定等血型血清学检查，该试剂制备具有成本低、工艺简单的优点，具有较好的推广应用和开发价值。     

A comparison of the bronchodilator activity of Sch 1000 and salbutamol.

The effects of the beta 2-adrenergic agonist, salbutamol, 200 mug, and the cholinergic antagonist, Sch 1000, 40 mug, have been compared in 25 asthmatic patients using a single dose, double-blind, crossover trial design. Salbutamol aerosol produces a greater degree of bronchodilatation than Sch 1000 aerosol during the initial three hours following drug administration. There is no significant difference in the bronchodilator effects of the two drugs in the interval four to eight hours after drug administration. Nonatopic patients showed less difference in bronchodilator response to each of the two drugs than atopic patients. Neither drug showed any significant adverse effect on blood pressure, pulse rate, or electrocardiogram. In six asthmatic patients the effect of the combination of salbutamol, 200 mug, and Sch 1000, 40 mug, was evaluated. The combination produced a longer duration of bronchodilatation than either drug alone when compared to placebo.